Therapeutics: Influenza A virus hemagglutinin (HA)

In vitro and mouse studies identified a broadly neutralizing antibody (bNAb) that could help treat influenza or design cross-reactive vaccines. The bNAb targeting the stem region of HA was isolated from a patient recovering from infection with the H1N1 subtype of influenza A virus. In viral neutralization assays, the bNAb neutralized all 10 of the influenza A group 2 subtypes tested and several group 1 subtypes. In mice challenged with a group 1 or group 2 subtype of influenza A virus, the bNAb administered 24 hours after challenge prevented infection in all animals. Next steps could include testing the bNAb in a non-human primate model of influenza A...